Recalcitrant pemphigus vulgaris responding to systemic tacrolimus

Dermatology

Volumn 221, Issue 2, 2010, Pages 122-126

  Büsing, Viola ^a   Kern, Johannes S ^a   Bruckner Tuderman, Leena ^a   Hofmann, Silke C ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Desmoglein 3; Immunosuppression; Pemphigus vulgaris; Tacrolimus

Indexed keywords

ATORVASTATIN; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; DESMOGLEIN 3 ANTIBODY; ENALAPRIL; HYDROCHLOROTHIAZIDE; METFORMIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMEPRAZOLE; PRAZOSIN; PREDNISOLONE; TACROLIMUS;

ADULT; AGED; ANTIBODY TITER; ARTICLE; BLISTER; CASE REPORT; CHEEK MUCOSA; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EROSION; FEMALE; GASTROINTESTINAL SYMPTOM; GINGIVA; HUMAN; HUMAN TISSUE; HYPERTENSION; LOWER LIP; MONOTHERAPY; MOUTH MUCOSA; MOUTH ULCER; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPOROSIS; PALATE; PATIENT MONITORING; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; RELAPSE; REMISSION; RESPIRATORY TRACT INFECTION; SEROLOGY; SIDE EFFECT; TREATMENT RESPONSE; UREA BLOOD LEVEL; WEIGHT REDUCTION;

ADRENAL CORTEX HORMONES; AGED; AUTOANTIBODIES; AZATHIOPRINE; CYCLOPHOSPHAMIDE; DAPSONE; DERMATOLOGIC AGENTS; DESMOGLEIN 3; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; MOUTH MUCOSA; MYCOPHENOLIC ACID; PEMPHIGUS; TACROLIMUS; TREATMENT OUTCOME;

EID: 77956342172     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314155     Document Type: Article

References (24)

1. Takae Y, Nishikawa T, Amagai M: Pemphigus mouse model as a tool to evaluate various immunosuppressive therapies. Exp Dermatol 2009; 18: 252-260.
2. Delva E, Jennings JM, Calkins CC, Kottke MD, Faundez V, Kowalczyk AP: Pemphigus vulgaris IgG-induced desmoglein-3 endocytosis and desmosomal disassembly are mediated by a clathrin- and dynamin-independent mechanism. J Biol Chem 2008; 283: 18303-18313.
3. Ding X, Aoki V, Mascaro JM Jr, Lopez-Swiderski A, Diaz LA, Fairley JA: Mucosal and mucocutaneous (generalized) pemphigus vulgaris show distinct autoantibody profiles. J Invest Dermatol 1997; 109: 592-596.
4. Cheng SW, Kobayashi M, Kinoshita-Kuroda K, Tanikawa A, Amagai M, Nishikawa T: Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3. Br J Dermatol 2002; 147: 261-265.
5. Martin LK, Werth V, Villanueva E, Segall J, Murrell DF: Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev 2009; 1:CD006263.
6. Zambruno G, Borradori L: Rituximab immunotherapy in pemphigus: therapeutic effects beyond B-cell depletion. J Invest Dermatol 2008; 128: 2745-2747.
7. Schmidt E, Zillikens D: Immunoadsorption in dermatology. Arch Dermatol Res 2010; 302: 241-253.
8. Madan V, Griffiths CE: Systemic ciclosporin and tacrolimus in dermatology. Dermatol Ther 2007; 20: 239-250.
9. Bystryn JC, Rudolph JL: Pemphigus. Lancet 2005; 366: 61-73.
10. Hofmann SC, Kautz O, Hertl M, Sticherling M, Zillikens D, Bruckner-Tuderman L: Results of a survey of German dermatologists on the therapeutic approaches to pemphigus and bullous pemphigoid. J Dtsch Dermatol Ges 2009; 7: 227-233.
11. Harman KE, Albert S, Black MM: Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003; 149: 926-937.
12. Thivolet J, Barthelemy H, Rigot-Muller G, Bendelac A: Effects of cyclosporin on bullous pemphigoid and pemphigus. Lancet 1985;i:334-335.
13. Ioannides D, Chrysomallis F, Bystryn JC: Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus. Arch Dermatol 2000; 136: 868-872.
14. Thomson AW, Bonham CA, Zeevi A: Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit 1995; 17: 584-591.
15. Gach JE, Ilchyshyn A: Beneficial effects of topical tacrolimus on recalcitrant erosions of pemphigus vulgaris. Clin Exp Dermatol 2004; 29: 271-272.
16. Termeer CC, Technau K, Augustin M, Simon JC: Topical tacrolimus (protopic) for the treatment of a localized pemphigus foliaceus. J Eur Acad Dermatol Venereol 2004; 18: 636-637.
17. Shlomchik MJ, Craft JE, Mamula MJ: From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol 2001; 1: 147-153.
18. Kwon EJ, Yamagami J, Nishikawa T, Amagai M: Anti-desmoglein IgG autoantibodies in patients with pemphigus in remission. J Eur Acad Dermatol Venereol 2008; 22: 1070-1075.
19. Ishii K, Lin C, Siegel DL, Stanley JR: Isolation of pathogenic monoclonal anti-desmoglein 1 human antibodies by phage display of pemphigus foliaceus autoantibodies. J Invest Dermatol 2008; 128: 939-948.
20. Yokouchi M, Saleh MA, Kuroda K, Hachiya T, Stanley JR, Amagai M, Ishii K: Pathogenic epitopes of autoantibodies in pemphigus reside in the amino-terminal adhesive region of desmogleins which are unmasked by proteolytic processing of prosequence. J Invest Dermatol 2009; 129: 2156-2166.
21. Pasricha JS, Khaitan BK, Raman RS, Chandra M: Dexamethasone- cyclophosphamide pulse therapy for pemphigus. Int J Dermatol 1995; 34: 875-882.
22. Saha M, Powell AM, Bhogal B, Black MM, Groves RW: Pulsed intravenous cyclophosphamide and methylprednisolone therapy in refractory pemphigus. Br J Dermatol 2009, E-pub ahead of print.
23. Shimanovich I, Nitschke M, Rose C, Grabbe J, Zillikens D: Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Br J Dermatol 2008; 158: 382-388.
24. Pfutze M, Eming R, Kneisel A, Kuhlmann U, Hoyer J, Hertl M: Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab. Dermatology 2009; 218: 237-245.